Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma

Next Previous
Search
Trial Profile

PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Acalabrutinib (Primary) ; CD47 antigen inhibitors (Primary) ; Ceralasertib (Primary) ; Danvatirsen (Primary) ; Rituximab (Primary) ; SRA 515 (Primary)
  • Indications Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Acronyms PRISM Study
  • Sponsors Acerta Pharma

    • Most Recent Events

    • 13 Dec 2022 Results (n=7; By 31 March 2021) assessing safety and efficacy of Arm 3 of the PRISM platform study of acalabrutinib with magrolimab and rituximab in all molecular subtypes of relapsed/refractory diffuse large B-cell lymphoma, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
    • 14 Dec 2021 Results (n=17) from treatment arm acalabrutinib with the anti-STAT3 allele-specific oligonucleotide AZD9150 , presented at the 63rd American Society of Hematology Annual Meeting and Exposition
    • 28 Apr 2021 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top